Måndag 3 Augusti | 16:22:36 Europe / Stockholm

Svenska | English

Pliant Therapeutics, Inc.

Vem äger bolaget?

All ägardata du vill ha finns i Holdings!

Filter

År

Typ

Språk

Rensa

2026-07-13 14:30:00 Pliant Therapeutics Names Flavia Borellini, Ph.D. and Robert Iannone, M.D., M.S.C.E. to Board of Directors

2026-05-21 23:29:30 Pliant Therapeutics Announces Upcoming Presentation at the 2026 American Society of Clinical Oncology Annual Meeting

2026-05-11 22:05:00 Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results

2026-05-06 14:30:00 Pliant Therapeutics to Participate in the RBC Capital Markets Global Healthcare Conference

2026-04-30 14:30:00 Pliant Therapeutics Announces First Patient Dosed in FORTIFY, the Phase 1b Indication Expansion Trial Evaluating PLN-101095 in Patients with ICI-Refractory Solid Tumors

2026-04-18 19:31:00 Pliant Therapeutics Announces Presentation of Updated Data from the Phase 1 Trial of PLN-101095 in Patients with ICI-Refractory Solid Tumors at the 2026 AACR Annual Meeting

2026-03-18 14:00:00 Pliant Therapeutics Announces Upcoming Presentation of Phase 1 Clinical Trial of PLN-101095 in Patients with Solid Tumors at the 2026 AACR Annual Meeting

2026-03-11 21:05:00 Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2025 Financial Results

2025-12-04 13:30:00 Pliant Therapeutics Announces Interim Data from PLN-101095 in Patients with Immune Checkpoint Inhibitor-Refractory Advanced Solid Tumors 1,31 USD | -14,94%

2025-12-01 14:30:00 Pliant Therapeutics to Participate in the Piper Sandler Healthcare Conference 1,53 USD | -4,97%

2025-11-06 22:05:00 Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results 1,53 USD | -6,71%

2025-08-07 22:05:00 Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results 1,68 USD | -0,59%

2025-06-27 22:05:00 Pliant Therapeutics Provides Update on BEACON-IPF 1,25 USD | -3,85%

2025-05-21 22:03:00 Pliant Therapeutics Presents Clinical and Preclinical Data at the American Thoracic Society International Conference 1,33 USD | -2,92%

2025-05-01 22:05:00 Pliant Therapeutics Announces Strategic Realignment of Workforce and Operations 1,62 USD | +1,89%

2025-04-07 22:05:00 Pliant Therapeutics Announces Upcoming Presentations at the 2025 American Thoracic Society International Conference 1,25 USD | -6,72%

2025-03-17 13:00:00 Pliant Therapeutics Announces Interim Phase 1 Data for PLN-101095 in Patients with Immune Checkpoint Inhibitor-Refractory Advanced Solid Tumors 1,70 USD | +10,39%

2025-03-13 12:20:00 Pliant Therapeutics Adopts Limited Duration Stockholder Rights Agreement 1,52 USD | -3,80%

2025-03-03 15:27:03 Pliant Therapeutics Provides Update on BEACON-IPF, a Phase 2b/3 Trial in Patients with Idiopathic Pulmonary Fibrosis 1,38 USD | -59,88%

2025-02-07 22:58:09 Pliant Therapeutics Provides Update on BEACON-IPF, a Phase 2b/3 Trial in Patients with Idiopathic Pulmonary Fibrosis 7,79 USD | -34,81%

2025-01-22 22:00:00 Pliant Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) 10,92 USD | -1,36%

2025-01-22 14:00:00 Pliant Therapeutics Appoints Delphine Imbert, Ph.D. as Chief Technical Officer 10,92 USD | -1,36%

2024-11-19 00:00:00 Pliant Therapeutics Presents Data from its Bexotegrast Program at The Liver Meeting® 2024 12,32 USD | -0,88%

2024-10-01 22:35:00 Pliant Therapeutics Appoints Gary Palmer, M.D. as Senior Vice President of Medical Affairs 10,55 USD | -5,89%

2024-09-30 22:45:00 Pliant Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) 11,21 USD | -0,88%

2024-08-28 14:00:00 Pliant Therapeutics to Participate in Upcoming Investor Events 12,88 USD | -1,75%

2024-08-26 15:10:07 Pliant Therapeutics Announces Four Upcoming Presentations at the European Respiratory Society International Congress 2024 13,45 USD | 0,00%

2024-08-07 22:05:00 Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results 12,54 USD | -4,35%

2024-08-06 22:03:00 Pliant Therapeutics to Participate in the Canaccord Genuity 44th Annual Growth Conference 13,11 USD | +1,47%

2024-06-13 22:05:00 Pliant Therapeutics Announces Appointment of Steve Krognes to Board of Directors 11,97 USD | +1,79%

2024-06-12 22:05:00 Pliant Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) 11,76 USD | +4,16%

2024-06-06 14:00:00 Pliant Therapeutics Presents Data from its Bexotegrast Program at the European Association for the Study of the Liver (EASL) International Liver Congress™ 11,54 USD | -4,63%

2024-05-22 00:50:00 Pliant Therapeutics Presents Data from its Bexotegrast Program at the American Thoracic Society International Conference 14,59 USD | -3,51%

2024-05-14 13:30:00 Pliant Therapeutics Announces Positive Topline Data from a Phase 2a Collagen PET Imaging Clinical Trial of Bexotegrast in Patients with Idiopathic Pulmonary Fibrosis 14,14 USD | +3,44%

2024-05-01 14:00:00 Pliant Therapeutics to Participate in Upcoming Investor Events 12,66 USD | +7,11%

2024-03-27 15:23:38 Pliant Therapeutics Announces Upcoming Presentations at the 2024 American Thoracic Society International Conference 14,55 USD | +2,90%

2024-03-12 12:30:00 Pliant Therapeutics Announces Accelerated Bexotegrast Development Plan for the Treatment of Idiopathic Pulmonary Fibrosis 15,14 USD | +4,20%

2024-02-27 22:03:00 Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2023 Financial Results 17,21 USD | +3,61%

2024-02-04 21:29:07 Pliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data from the INTEGRIS-PSC Phase 2a Trial of Bexotegrast 320 mg in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis

2024-01-03 14:00:00 Pliant Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference 18,06 USD | +0,56%

2023-11-13 22:30:00 Pliant Therapeutics Presentations at The Liver Meeting® 2023 Highlight Bexotegrast, an Inhibitor of αvß6 and αvß1 Integrins, in Primary Sclerosing Cholangitis 12,85 USD | -7,09%

2023-10-31 21:03:07 Pliant Therapeutics Announces Three Presentations at the Annual Meeting of the Society for Immunotherapy of Cancer 14,67 USD | +5,16%

2023-10-19 14:00:00 Pliant Therapeutics INTEGRIS-PSC Phase 2a Interim Data Evaluating Bexotegrast in Primary Sclerosing Cholangitis to be Highlighted in an Oral Late-Breaking Presentation at The Liver Meeting® 2023 13,88 USD | +2,44%

2023-10-16 22:05:00 Pliant Therapeutics Appoints S. Mishima Gerhart as Chief Regulatory Officer 15,40 USD | +0,98%

2023-09-25 22:05:00 Pliant Therapeutics to Host Investor Call and Webcast to Discuss Interim Results from INTEGRIS-PSC, a Phase 2a Trial in Patients with Primary Sclerosing Cholangitis 14,58 USD | -2,86%

2023-08-30 14:00:00 Pliant Therapeutics to Participate in Upcoming Investor Conferences 16,71 USD | +0,72%

2023-08-28 22:05:00 Pliant Therapeutics Announces Three Upcoming Presentations at the European Respiratory Society International Congress 2023 16,55 USD | +1,78%

2023-08-09 22:03:00 Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results 18,18 USD | +0,06%

Visa fler

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode